Crossmark

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity

Crossref DOI link: https://doi.org/10.1186/s13019-018-0829-z

Published Online: 2019-01-09

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aravot, Dan

Barac, Yaron D. http://orcid.org/0000-0002-4688-2358
Krutzwald-Josefson, Efrat

Allen, Aaron M.

Flex, Dov

Peled, Nir

Kramer, Mordechai R.

Peysakhovich, Yuri

Saute, Milton
License Information

Text and Data Mining valid from 2019-01-09
More Information

Article History

Received: 25 September 2018

Accepted: 28 December 2018

First Online: 9 January 2019

Change Date: 12 February 2019

Change Type: Correction

Change Details: The original article [1] contained an error whereby all authors’ names were mistakenly inverted. This error has now been corrected.

Ethics approval and consent to participate

: Retrospective study, was approved by the ethics committee at RMC, Israel.

: Approve.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.